PEG-PEI/siROCK2 Protects Against Aβ42-Induced Neurotoxicity in Primary Neuron Cells for Alzheimer Disease

Cellular and Molecular Neurobiology
Yunyun LiuZhonglin Liu

Abstract

Gene therapy that targets the ROCK2 gene has yielded promising results in the treatment of AD. Our previous study indicated that PEG-PEI/siROCK2 could effectively suppress ROCK2 mRNA expression and showed a promising prospect for the treatment of Alzheimer's disease. However, the ability of PEG-PEI/siROCK2 to reduce Aβ-induced cytotoxicity is unknown. To investigate the effect of PEG-PEI/siROCK2 against Aβ42-induced neurotoxicity, primary cultured cortical neurons were pretreated with PEG-PEI/siROCK2 for 24 h and then treated with 5 μM Aβ42 for 24 h. We found that PEG-PEI/siROCK2 increased the cell viability and reduced the number of apoptotic cells induced by Aβ42, as measured using an MTT assay and Annexin V/PI staining. A further study revealed that PEG-PEI/siROCK2 can activate p-Akt, and treatment with the PI3K inhibitor LY294002 attenuated the neuroprotective effects. These results suggest that PEG-PEI/siROCK2 prevents Aβ42-induced neurotoxicity and that the activation of PI3K/Akt pathway is involved in neuroprotection. Taken together, these findings shed light on the role of PEG-PEI/siROCK2 as a potential therapeutic agent for AD.

References

Nov 18, 2000·Experimental Cell Research·M AmanoK Kaibuchi
Mar 5, 2003·Cellular Microbiology·Jeffrey S Schorey, Andrea M Cooper
Mar 29, 2005·Nature Cell Biology·Zhong LiDianqing Wu
Feb 18, 2010·Journal of Cellular and Molecular Medicine·Per NilssonTakaomi C Saido
Apr 17, 2010·Toxicological Sciences : an Official Journal of the Society of Toxicology·Tsan-Ju ChenShun-Sheng Chen
Jan 5, 2012·Journal of Alzheimer's Disease : JAD·Alexander Navarrete SantosHarald Hampel
May 1, 2012·Biochemical and Biophysical Research Communications·Yanran LiangEnxiang Tao
Jun 7, 2012·Cell Biochemistry and Biophysics·Ashley R MurrayAnna A Shvedova
Jan 17, 2013·Stem Cells and Development·Micaela Johanna Glat, Daniel Offen
Jan 24, 2013·Translational Psychiatry·L ManterolaJ L Zugaza
Nov 16, 2013·Journal of Controlled Release : Official Journal of the Controlled Release Society·G PurasJ L Pedraz
Dec 7, 2013·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Jeremy H HerskowitzJames J Lah
Dec 20, 2013·The International Journal of Neuroscience·Xiaojun WenJingyang Hu
Apr 15, 2014·Biochemical and Biophysical Research Communications·Xinglei YaoJian-Qing Gao
Nov 12, 2014·Nanoscale Research Letters·Zhongyang KouLiang Guo

❮ Previous
Next ❯

Citations

Nov 1, 2018·Current Medicinal Chemistry·Fei HaoJing Xie
Oct 30, 2019·Molecular Biology Reports·Shashank Shekhar, Sharmistha Dey
Feb 1, 2020·Cellular and Molecular Neurobiology·Hualong WangShengdi Chen
Apr 30, 2021·Frontiers in Cellular Neuroscience·Benoit SchneiderJean-Marie Launay
Nov 5, 2017·Langmuir : the ACS Journal of Surfaces and Colloids·Xinghong DuoWencheng Zhang

❮ Previous
Next ❯

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.